MoneyWorks4Me

Lasa Supergenerics board approves financial results

16 Aug 2021 Evaluate
Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 Lasa Supergenerics has informed that the Board of Directors in their meeting held on August 14, 2021 which was commenced at 12:00 Noon and concluded at 03: 30 pm has considered and approved the statement of un-audited financials result along with Limited Review Report for the quarter ended June 30, 2021.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..